TY - JOUR T1 - Assessment of patient engagement and adherence with once-daily indacaterol/glycopyrronium/mometasone (IND/GLY/MF) Breezhaler digital companion in asthma: interim analysis from Germany JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.OA3948 VL - 58 IS - suppl 65 SP - OA3948 AU - Holger Woehrle AU - Paul Mastoridis AU - David A Stempel AU - Leanne Kaye AU - Connelly Doan AU - Karen Mezzi Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/OA3948.abstract N2 - Introduction: Inadequate adherence to inhaled asthma therapy is associated with poor clinical outcomes. Digital companion paired inhaler devices may improve treatment adherence. Once-daily IND/GLY/MF Breezhaler®, approved in EU for inadequately controlled asthma, included the first digital companion (sensor and smartphone application [app]) that can be prescribed alongside treatment. This interim analysis from Germany assessed treatment adherence and engagement with IND/GLY/MF Breezhaler® digital companion in patients with asthmaMethods: Patients (≥18y) prescribed Breezhaler® digital companion for ≥30 days were included. Assessments by age group: mean % medication adherence (no. of puffs taken/prescribed×100 [days 15–30 and 76–90]); mean % app engagement (opening and viewing ≥1 app feature over the first 30 days)Results: Of 135 enrolled patients (mean age: 47y), 117 had ≥1 month adherence data. Mean baseline adherence was 82% (68–90% across age groups). Mean baseline app engagement was 72% (68–75% across age groups). At 3-month follow-up (n=42), mean daily adherence was 82% (Table)Conclusions: Patients using Breezhaler® digital companion showed good medication adherence (82%) and app engagement. Long-term data from this program may help understand factors associated with improved medication adherence and app engagement in these patientsFootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA3948.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -